A comprehensive review of everolimus clinical reports: A new mammalian target of rapamycin inhibitor

Transplantation

Volumn 94, Issue 7, 2012, Pages 659-668

  Gurk Turner, Cheryle ^a   Manitpisitkul, Wana ^a   Cooper, Matthew ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Everolimus; Immunosuppression; Proliferation signal inhibitor; Review; Solid organ transplantation

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CELLCELPT; CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

ANEMIA; BACTERIAL INFECTION; CARDIAC ALLOGRAFT VASCULOPATHY; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSLIPIDEMIA; GINGIVA DISEASE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INFECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG TRANSPLANTATION; MONOTHERAPY; MOUTH ULCER; NAUSEA; NEPHROTOXICITY; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SIDE EFFECT; STEADY STATE; URINARY TRACT INFECTION; VIRUS INFECTION; WOUND HEALING; WOUND HEALING IMPAIRMENT;

EVIDENCE-BASED MEDICINE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; TIME FACTORS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84867271597     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31825b411c     Document Type: Review

References (54)

1. Kovarik JM, Eisen H, Doren R, et al. Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence of cyclosporine exposure. J Heart Lung Transplant 2003; 22: 117.
2. Kovarik JM, Dantal J, Vivati G, et al. Influence of delayed initiation of cyclosporine on Everolimus pharmacokinetics in de novo renal transplant patients. Am J Transplant 2003; 3: 1576.
3. Kovarik JM, Kaplan B, Tedesco Silva H, et al. Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. Am J Transplant 2003; 3: 606.
4. Buddle K, Neumayer HH, Lehne G, et al. Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients. Nephrol Dial Transplant 2004; 19: 2606.
5. Strom T, Haschke M, Zhang YL, et al. Identification of everolimus metabolite patterns in trough blood samples of kidney transplant patients. Ther Drug Monit 2007; 29: 592.
6. Brandhorst G, Tenderich G, Zittermann A, et al. Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor. Ther Drug Monit 2008; 30: 113.
7. Pascual J, del Castillo D. Cabello M, et al. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. Transplantation 2010; 89: 994.
8. Picard N, Rouguieg-Malki K, Kamar N, et al. CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics n renal transplant recipients. Transplantation 2011; 91: 652.
9. Kovarik JM, Kaplan B, Tedesco Silva H, et al. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation 2002; 27: 920.
10. Kovarik JM, Tedesco H, Pacual J, et al. Everolimus therapeutic concentration range defined from a prospective trial with reducedexposure cyclosporine in de novo kidney transplantation. Ther Drug Monit 2004; 26: 499.
11. Khoschsorur GA, Fruehwirth F, Zelzer S, et al. Comparison of fluorescent polarization immunoassay (FPIA) versus HPLC to measure everolimus blood concentrations in clinical transplantation. Clin Chim Acta 2007; 380: 217.
12. Starling RC, Hare JM, Hauptman P, et al. Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposureeffect modeling. Am J Transplant 2004; 4: 2126.
13. Zortress (everolimus) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; 2010.
14. Affinitor (everolimus) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; 2009.
15. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847.
16. Vigano M, Tuzcu M, Benza R, et al. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. J Heart Lung Transplant 2007; 26: 584.
17. Lehmkuhl HB, Mai D, Dandle M, et al. Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients. J Heart Lung Transplant 2007; 26: 700.
18. Rothenburger M, Teerling E, Bruch C, et al. Calcineurin inhibitorY free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up. J Heart Lung Transplant 2007; 26: 250.
19. Schweiger M, Wasler A, Prenner G, et al. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients. Transpl Immunol 2006; 16: 46.
20. Snell GI, Valentine VG, Vitulo P, et al. Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am J Transplant 2006; 6: 169.
21. Gullestad L, Iversen M, Mortensen SA, et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation 2010; 89: 864.
22. Gullestad L, Mortensen SA, Eiskjaer H, et al. Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial. Transplantation 2010; 90: 1581.
23. Ross H, Pflugfelder P, Haddad H, et al. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients. J Heart Lung Transplant 2008; 27: 197.
24. Ross H, Pflugfelder P, Haddad H, et al. Reduction of cyclosporine following the introduction of everolimus in maintenance heart transplant recipients: a pilot study. Transpl Int 2010; 23: 31.
25. Lopez JAM, Almenar L, Martinez-Dolz L, et al. Progression of renal dysfunction in cardiac transplantation after the introductionof everolimus in the immunosuppressive regime. Transplantation 2009; 87: 538.
26. Potena L, Gianchi I, Magnani G, et al. Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: a randomized study. Transplantation 2010; 89: 263.
27. Gude E, Gullestad L, Arora S, et al. Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation. J Heart Lung Transplant 2010; 29: 641.
28. Lehmkuhl HB, Arizon J, Vigano M, et al. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. Transplantation 2009; 88: 115.
29. Kahan BD, Wong RL, Carter C, et al. A phase 1 study of a 4-week course of SDZ-RAD (RAD) in quiescent cyclosporine-prednisoneYtreated renal transplant recipients. Transplantation 1999; 68:1100.
30. Kahan BD, Kaplan B, Lorber MI, et al. RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation 2001; 71: 1400.
31. Vitko S, Margreiter R, Wimar W, et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004; 78: 1532.
32. Vitko S, Margreiter R, Weimar W, et al. Three-year efficacy and safety results from a study of Everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5: 2521.
33. Lorber MI, Mulgaonkar S, Butt KMH, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005; 80: 244.
34. Nashan B, Curtis J, Ponticelli C, et al. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized,multicenter, open-label study. Transplantation 2004; 78: 1332.
35. Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 626.
36. Tedesco-Silva Jr J, Vitko S, Pascual J, et al. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int 2007; 20: 27.
37. Salvadori M, Scolari MP, Bertoni E, et al. Everolimus with very lowexposure cyclosporine A in de novo kidney transplantation: a multicenter, randomized, controlled trial. Transplantation 2009; 88: 1194.
38. Tedesco Silva H, Cibrik D, Johnston T, et al. Everolimus plus reducedexposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010; 10: 1401.
39. Albano L, Berthoux F, Moal MC, et al. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. Transplantation 2009; 88: 69.
40. Dantal J, Berthoux R, Moal MC, et al. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int 2010; 23: 1084.
41. Buddle K, Becker T, Arms W, et al. Everolimus-based, calcineurininhibitorYfree regimen in recipients of de-novo kidney transplant: an open-label, randomized, controlled trial. Lancet 2011; 377: 837.
42. MontagninoG, Sandrini S, Lorio B, et al. A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine. Nephrol Dial Transplant 2008; 23: 707.
43. Chan L, Greenstein S, Hardy MA, et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation 2008; 85: 821.
44. Chan L, Harmann E, Cibrik D, et al. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. Transplantation 2010; 90: 31.
45. Levy GA, Grant D, Paradis K, et al. Pharmacokinetics and tolerability of 40-O-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients. Transplantation 2001; 71: 160.
46. Levy G, Schmidi H, Punch J, et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12-and 36-month results. Liver Transpl 2006; 12: 1640.
47. Vallin M, Guillaud O, Morard I, et al. Tolerability of everolimus-based immunosuppression in maintenance liver transplant recipients. Clin Transplant 2010; 10: 1.
48. De Simone P, Carrai P, Precisi A, et al. Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function. Transpl Int 2009; 22: 279.
49. Pascual J, Marcen R, Ortuno J. Clinical experience with everolimus (Certican) in elderly recipients: the "old-for-old" concept. Transplantation 2005; 79: S85.
50. Castroagudin JF, Molina E, Romero R, et al. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Liver Transpl 2009; 15: 1792.
51. De Simone P, Metselaar HJ, Fischer L, et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl 2009; 15: 1262.
52. Saliba F, Dharancy S, Lorho R, et al. Conversion to everolimus in maintenance liver transplant patients: a multicenter retrospective analysis. Liver Transpl 2011; 17: 905.
53. Masetti M, Montalti R, Rompianesi G, et al. Early withdrawal of calcineurin inhibitors and everolimusmonotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant 2010; 10: 1.
54. Rapamune (sirolimus) [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals; 2011.